Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®

Clinical trial NCT07495930 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07495930
Sponsor: Shanghai Henlius Biotech
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Health Adult Subjects

Start date: 2026-04-30
Primary completion: 2026-07-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.